Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

ARNA 4.04 -0.24 (-5.61%)
price chart
Arena Pharmaceuticals Misses Q4 Expectations
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) reported financial results Monday for the fourth quarter and full year ended December 31, 2014.
Stock To Watch : Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)  Markets Wired
Arena Misses On Earnings: Investors Need To Look Deeper (ARNA)  Seeking Alpha (registration)
Earnings Reaction History: Arena Pharmaceuticals, Inc., 42.9% Follow-Through ...
Arena Pharmaceuticals, Inc. ( ARNA ) is due to issue its quarterly earnings report in the upcoming extended-hours session.
Arena Pharmaceuticals, Inc. Price Target Update
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): According to 5 Analysts, The short term target price has been estimated at $ 7.3.
Why Arena Pharmaceuticals, Inc. Shares Jumped 24% in January
What: Shares of Arena Pharmaceuticals (NASDAQ: ARNA ) , a biopharmaceutical company primarily focused on developing therapies for weight management and to treat autoimmune diseases, jumped 24% in January per S&P Capital IQ after reporting ...
Arena Pharmaceuticals Inc. (ARNA) is Trading Lower on Unusual Volume for ...
Arena Pharmaceuticals Inc. ($ARNA) experienced unusually high volume on Mar. 03, as the stock lost 5.61% to a closing price of $4.04.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Kept in Lower Notes- Westar ...
Biopharmaceutical company, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) [Trend Analysis] plunged over 2.34% in afterhours trading on Monday after it released that a loss for the Q4 that widened from previous year, despite a revenue increase, reflecting ...
Arena Pharmaceuticals' Belviq Set To Surge In 2015
It might also be said that, when examining cyclical trends in any kind of market, those that learn from history may be better positioned to take advantage of a repeat performance.
Will Arena Pharmaceuticals (ARNA) Disappoint on Q4 Earnings?
Arena Pharmaceuticals, Inc. (ARNA - Snapshot Report) is scheduled to report fourth-quarter 2014 results on Mar 2. Last quarter, the company posted a positive earnings surprise of 61.54%.
Will Arena Pharmaceuticals (ARNA) Disappoint on Q4 Earnings? - Analyst Blog  Nasdaq
Analyst Rating Update on Arena Pharmaceuticals, Inc.
Analysts at Zacks have given a short term rating of hold on Arena Pharmaceuticals (NASDAQ:ARNA) with a rank of 3. The counter has received an average rating of 2.29 from 7 brokerage firms.
Price Target Update on Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) should head towards $6.83 per share according to 6 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $5 per share.